|
Biota Holdings Limited - Company Profile Snapshot
| Company Profile: |
Biota Holdings Limited |
| Ticker: |
BTA |
| Exchanges: |
SYD |
| 2009 Sales: |
57,616,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
AUSTRALIA |
| Employees: |
34 |
Business Description
Biota Holdings Limited. The Group's principal activity is discovering and developing antiviral drugs. The Group's operation focuses on the development of Zanamivir, neuraminidase inhibitor for the treatment and prevention of influenza. Its research outcomes have included nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim, and a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease. It operates in Australia.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
